Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore cutting-edge advancements in blood-based biomarker research for neurodegenerative diseases in this comprehensive webinar featuring presentations from Dr. Doug Hinerfeld, Dr. Maura Malpetti, and Dr. Sterling Johnson. Discover how Alamar Biosciences' highly sensitive NULISAâ„¢ immunoassay technology is revolutionizing multiplex proteomic analysis to unlock new insights into Alzheimer's disease (AD) and other neurodegenerative disorders. Learn about crucial applications for early detection, differential diagnosis, and disease monitoring through novel findings from Cambridge-based cohorts and the Wisconsin Registry for Alzheimer's Prevention (WRAP) study. Examine how blood biomarkers, including pTau, NfL, and inflammation markers, are reshaping understanding of AD progression, multi-etiology dementia, and survival prediction. Understand Dr. Malpetti's research on the role of inflammation and neurodegeneration in diseases beyond AD, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP), while exploring Dr. Johnson's work on identifying mixed-pathology dementia challenges and how emerging biomarker tools enhance precision medicine approaches. Gain insights into the translational impact of large-scale proteomic screening, integration of blood-based markers with imaging modalities, and the future of biomarker-driven clinical trials. Receive an overview of Alamar's innovative NULISA technology and its role in accelerating discoveries in neurodegenerative research, followed by a live Q&A session with the expert presenters.
